Blood marker may guide antiviral treatment duration for respiratory infections
NCT ID NCT06668025
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether measuring a protein called MxA in the blood can help doctors decide when to stop antiviral drugs in patients with flu or COVID-19. Researchers enrolled 86 adults and compared standard care to MxA-guided treatment. The goal was to see if the test could reduce symptom recurrence and shorten hospital stays.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MxA blood test
- What this could lead to
- If successful, this could help doctors personalize antiviral treatment duration, potentially reducing unnecessary drug use and hospital stays.
- What could go wrong
- This is a small pilot study with only 86 participants, so results may not apply broadly. The MxA test may not reliably guide treatment decisions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLUENZA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
China-Japan Friendship hospital
Beijing, Beijing Municipality, 100029, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Flu vaccine showdown: which shot protects seniors best?
- Can a simple breath test catch flu in High-HIV regions?
- Can a new pill keep High-Risk COVID-19 patients out of the hospital?
- Can a simple mask stop the flu? 2,000 volunteers put it to the test
- Can a stronger flu shot better protect seniors?
- Flu shot showdown: Cell-Grown vs recombinant vaccine put to the test